Diagnosis and Treatment of Polycythemia Vera

Douglas Tremblay; Marina Kremyanskaya; John Mascarenhas; Ronald Hoffman

doi:10.1001/jama.2024.20377

journal article Jan 14, 2025

Diagnosis and Treatment of Polycythemia Vera

Douglas Tremblay Marina Kremyanskaya John Mascarenhas

Ronald Hoffman

JAMA Vol. 333 No. 2 pp. 153 · American Medical Association (AMA)

View at Publisher Save 10.1001/jama.2024.20377

Abstract

ImportancePolycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 persons.ObservationsErythrocytosis (hemoglobin &amp;gt;16.5 mg/dL in men or &amp;gt;16.0 mg/dL in women) is a required diagnostic criterion, although thrombocytosis (53%) and leukocytosis (49%) are common. Patients may have pruritus (33%), erythromelalgia (5.3%), transient visual changes (14%), and splenomegaly (36%) with abdominal discomfort. More than 95% of patients have a JAK2 gene variant, which helps distinguish PV from secondary causes of erythrocytosis, such as tobacco smoking or sleep apnea. Among 7 cohorts (1545 individuals), the median survival from diagnosis was 14.1 to 27.6 years. Prior to or at the time of PV diagnosis, arterial thrombosis occurred in 16% of patients and 7% had venous thrombotic events, which could involve unusual sites, such as splanchnic veins. PV is also associated with an increased bleeding risk, especially in patients with acquired von Willebrand disease, which can occur with extreme thrombocytosis (platelet count, ≥1000 × 109/L). All patients with PV should receive therapeutic phlebotomy (goal hematocrit, &amp;lt;45%) and low-dose aspirin (if no contraindications). Patients who are at higher risk of thrombosis include those aged 60 years or older or with a prior thrombosis. These patients and those with persistent PV symptoms may benefit from cytoreductive therapy with hydroxyurea or interferon to lower thrombosis risk and decrease symptoms. Ruxolitinib is a Janus kinase inhibitor that can alleviate pruritus and decrease splenomegaly in patients who are intolerant of or resistant to hydroxyurea. About 12.7% of patients with PV develop myelofibrosis and 6.8% develop acute myeloid leukemia.Conclusions and RelevancePV is a myeloproliferative neoplasm characterized by erythrocytosis and is almost universally associated with a JAK2 gene variant. PV is associated with an increased risk of arterial and venous thrombosis, hemorrhage, myelofibrosis, and acute myeloid leukemia. To decrease the risk of thrombosis, all patients with PV should be treated with aspirin and therapeutic phlebotomy to maintain a hematocrit of less than 45%. Cytoreductive therapies, such as hydroxyurea or interferon, are recommended for patients at high risk of thrombosis.

Topics

No keywords indexed for this article. Browse by subject →

References

63

[1]

Tefferi "Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study." Leukemia (2013) 10.1038/leu.2013.163

[2]

Shallis "Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms." Hematol Oncol Clin North Am (2021) 10.1016/j.hoc.2020.11.005

[3]

Leal "Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort." Int J Cancer (2014) 10.1002/ijc.28492

[4]

Seaman "Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania." Cancer Epidemiol Biomarkers Prev (2009) 10.1158/1055-9965.epi-08-0922

[5]

Landgren "Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden." Blood (2008) 10.1182/blood-2008-03-143602

[6]

Hultcrantz "Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study." Ann Intern Med (2018) 10.7326/m17-0028

[7]

Gerds "Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL." Blood (2023) 10.1182/blood.2023020232

[8]

Finazzi "A prospective analysis of thrombotic events in the European collaboration study on Low-Dose Aspirin in Polycythemia (ECLAP)." Pathol Biol (Paris) (2004) 10.1016/j.patbio.2004.02.007

[9]

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson et al.

Blood 2014 10.1182/blood-2014-05-579136

[10]

Levine "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis." Cancer Cell (2005) 10.1016/j.ccr.2005.03.023

[11]

James "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera." Nature (2005) 10.1038/nature03546

[12]

Kralovics "A gain-of-function mutation of JAK2 in myeloproliferative disorders." N Engl J Med (2005) 10.1056/nejmoa051113

[13]

Baxter "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders." Lancet (2005) 10.1016/s0140-6736(05)71142-9

[14]

Jamieson "The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation." Proc Natl Acad Sci U S A (2006) 10.1073/pnas.0601462103

[15]

Scott "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis." N Engl J Med (2007) 10.1056/nejmoa065202

[16]

Williams "Life histories of myeloproliferative neoplasms inferred from phylogenies." Nature (2022) 10.1038/s41586-021-04312-6

[17]

Van Egeren "Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms." Cell Stem Cell (2021) 10.1016/j.stem.2021.02.001

[18]

Cordua "Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population." Blood (2019) 10.1182/blood.2019001113

[19]

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al.

New England Journal of Medicine 2017 10.1056/nejmoa1701719

[20]

Pearson "Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia." Lancet (1978) 10.1016/s0140-6736(78)92098-6

[21]

Zwicker "Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study." Haematologica (2022) 10.3324/haematol.2021.279032

[22]

Marchioli "Vascular and neoplastic risk in a large cohort of patients with polycythemia vera." J Clin Oncol (2005) 10.1200/jco.2005.07.062

[23]

Yang "Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography." Br J Haematol (2013) 10.1111/bjh.12290

[24]

Cerquozzi "Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients." Blood Cancer J (2017) 10.1038/s41408-017-0035-6

[25]

Smalberg "Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis." Blood (2012) 10.1182/blood-2011-09-376517

[26]

De Stefano "Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district: pooled analysis of 1500 cases." Blood Cancer J (2018) 10.1038/s41408-018-0151-y

[27]

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al.

Blood 2022 10.1182/blood.2022015850

[28]

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury, Eric Solary, Oussama Abla et al.

Leukemia 2022 10.1038/s41375-022-01613-1

[29]

Wouters "Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis." Blood Adv (2020) 10.1182/bloodadvances.2020003323

[30]

Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases

Patrick G. Northup, Juan Carlos Garcia‐Pagan, Guadalupe Garcia‐Tsao et al.

Hepatology 2021 10.1002/hep.31646

[31]

Gerds "Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology." J Natl Compr Canc Netw (2022) 10.6004/jnccn.2022.0046

[32]

Barbui "Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet." Leukemia (2018) 10.1038/s41375-018-0077-1

[33]

Di Nisio "The haematocrit and platelet target in polycythemia vera." Br J Haematol (2007) 10.1111/j.1365-2141.2006.06430.x

[34]

Alvarez-Larrán "Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea." Haematologica (2017) 10.3324/haematol.2016.152769

[35]

Guglielmelli "JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis." Blood Cancer J (2021) 10.1038/s41408-021-00581-6

[36]

Passamonti "A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications." Leukemia (2010) 10.1038/leu.2010.148

[37]

Marchioli "Cardiovascular events and intensity of treatment in polycythemia vera." N Engl J Med (2013) 10.1056/nejmoa1208500

[38]

Zangari "Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?" Blood Coagul Fibrinolysis (2013) 10.1097/mbc.0b013e32835bfdb9

[39]

Landolfi "Efficacy and safety of low-dose aspirin in polycythemia vera." N Engl J Med (2004) 10.1056/nejmoa035572

[40]

Mascarenhas "A randomized phase 3 trial of interferon-a vs hydroxyurea in polycythemia vera and essential thrombocythemia." Blood (2022) 10.1182/blood.2021012743

[41]

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al.

The Lancet Haematology 2020 10.1016/s2352-3026(19)30236-4

[42]

Yacoub "Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea." Blood (2019) 10.1182/blood.2019000428

[43]

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer et al.

New England Journal of Medicine 2015 10.1056/nejmoa1409002

[44]

Barbui "Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera." NEJM Evid (2023) 10.1056/evidoa2200335

[45]

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer et al.

The Lancet Haematology 2022 10.1016/s2352-3026(22)00046-1

[46]

Barbui "Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K): a nested case-control study." Leukemia (2019) 10.1038/s41375-019-0487-8

[47]

Barbui "A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study." Am J Hematol (2017) 10.1002/ajh.24851

[48]

Barosi "A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process." Br J Haematol (2010) 10.1111/j.1365-2141.2009.08019.x

[49]

Alvarez-Larrán "Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera." Br J Haematol (2016) 10.1111/bjh.13886

[50]

Maze "Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis." JAMA Netw Open (2019) 10.1001/jamanetworkopen.2019.12666

Showing 50 of 63 references

Metrics

28

Citations

63

References

Details

Published: Jan 14, 2025
Vol/Issue: 333(2)
Pages: 153

Authors

D

Douglas Tremblay

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

M

Marina Kremyanskaya

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

J

John Mascarenhas

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

R

Ronald Hoffman

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Cite This Article

Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, et al. (2025). Diagnosis and Treatment of Polycythemia Vera. JAMA, 333(2), 153. https://doi.org/10.1001/jama.2024.20377

Diagnosis and Treatment of Polycythemia Vera

You May Also Like